FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Teva's fixed-dose combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate for HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (Efavirenz; Emtricitabine; Tenofovir disoproxil fumarate)

Snippet

SUPPL AP for EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)